rotation.to
Following this device: dark.
Free account
rotation.to
Sign in / Request free access
Appearance
Following this device: dark.
Drag a card by its title · ⚙ to size, swap or remove

Who

Charles N. York II

COO and CFO

Company insider

Files Form 4 as: COO and CFO, Day One Biopharmaceuticals; Chief Financial Officer and VP, Spyre Therapeutics.

Every Form 4 they filed

In numbers

Trades disclosed
186
Buys
6
Sells
30
Bought
$116K
Sold
$3.4M
Companies
2
Companies where not an officer
0
First trade
12 Apr 2016
Last trade
23 Apr 2026
Last filed
23 Apr 2026

Companies traded

Where they are an officer
Day One BiopharmaceuticalsOfficer · Biotechnology · last 23 Apr 20260 buys · 30 sells
SYRE Spyre TherapeuticsOfficer · Biotechnology · last 14 Feb 20206 buys · 0 sells

Activity over time

1 Nov 2024 – 1 Oct 2026
10Nov 24May 25Nov 25Apr 26Oct 26

Buys above the line, sells below, each month.

Every trade

TradedCompanyWhatAmount
23 Apr 2026filed 23 Apr 2026Day One BiopharmaceuticalsBiotechnologySEC FORM 4 Code D—312,025filing
23 Apr 2026filed 23 Apr 2026Day One Biopharmaceuticalsoption or derivative · BiotechnologySEC FORM 4 Code D—72,875filing
23 Apr 2026filed 23 Apr 2026Day One Biopharmaceuticalsoption or derivative · BiotechnologySEC FORM 4 Code D—118,125filing
23 Apr 2026filed 23 Apr 2026Day One Biopharmaceuticalsoption or derivative · BiotechnologySEC FORM 4 Code D—497,667filing
23 Apr 2026filed 23 Apr 2026Day One Biopharmaceuticalsoption or derivative · BiotechnologySEC FORM 4 Code D—151,000filing
23 Apr 2026filed 23 Apr 2026Day One Biopharmaceuticalsoption or derivativeSEC FORM 4 Code D—497,667filing
23 Apr 2026filed 23 Apr 2026Day One Biopharmaceuticalsoption or derivativeSEC FORM 4 Code D—151,000filing
23 Apr 2026filed 23 Apr 2026Day One Biopharmaceuticalsoption or derivativeSEC FORM 4 Code D—116,000filing
23 Apr 2026filed 23 Apr 2026Day One Biopharmaceuticalsoption or derivativeSEC FORM 4 Code D—162,000filing
23 Apr 2026filed 23 Apr 2026Day One Biopharmaceuticalsoption or derivativeSEC FORM 4 Code D—162,000filing
23 Apr 2026filed 23 Apr 2026Day One Biopharmaceuticalsoption or derivativeSEC FORM 4 Code D—188,000filing
23 Apr 2026filed 23 Apr 2026Day One Biopharmaceuticalsoption or derivativeSEC FORM 4 Code D—6,750filing
23 Apr 2026filed 23 Apr 2026Day One Biopharmaceuticalsoption or derivativeSEC FORM 4 Code D—46,375filing
23 Apr 2026filed 23 Apr 2026Day One Biopharmaceuticalsoption or derivativeSEC FORM 4 Code D—72,875filing
23 Apr 2026filed 23 Apr 2026Day One Biopharmaceuticalsoption or derivativeSEC FORM 4 Code D—118,125filing
23 Apr 2026filed 23 Apr 2026Day One Biopharmaceuticalsoption or derivative · BiotechnologySEC FORM 4 Code D—116,000filing
23 Apr 2026filed 23 Apr 2026Day One Biopharmaceuticalsoption or derivative · BiotechnologySEC FORM 4 Code D—162,000filing
23 Apr 2026filed 23 Apr 2026Day One Biopharmaceuticalsoption or derivative · BiotechnologySEC FORM 4 Code D—162,000filing
23 Apr 2026filed 23 Apr 2026Day One Biopharmaceuticalsoption or derivative · BiotechnologySEC FORM 4 Code D—188,000filing
23 Apr 2026filed 23 Apr 2026Day One Biopharmaceuticalsoption or derivative · BiotechnologySEC FORM 4 Code D—6,750filing

Sectors

Health Care7
Not placed30

Buys in green, sells in red, by the company’s sector.

Related people

Scott L. BurrowsChief Financial Officer · Chief Financial Officer at Spyre Therapeutics, filing Form 4 there in the last year
Heidy King-JonesOfficer · Officer at Spyre Therapeutics, filing Form 4 there in the last year
Cameron TurtleChief Executive Officer · Chief Executive Officer at Spyre Therapeutics, filing Form 4 there in the last year
Jeffrey W. AlbersDirector · Director at Spyre Therapeutics, filing Form 4 there in the last year
Sheldon SloanChief Medical Officer · Chief Medical Officer at Spyre Therapeutics, filing Form 4 there in the last year